With the supply of HPV vaccines dwindling, doctors and researchers are concerned about what this means for the spread of the disease. According to recent projections, there won’t be a sufficient number of HPV vaccine doses available to meet global demand until at least 2024. However, new research may provide a possible solution to the HPV vaccine shortage.
In an OBGYN News article published on May 29, 2019, follow-up results from major phase 3 randomized controlled trials of bivalent HPV vaccine in Costa Rica and quadrivalent vaccine in India were shared. These trials deliver promising evidence that a single HPV dose could provide protection against infection for 11 years or more. Since children who receive the vaccine at the recommended age currently receive two doses, this could potentially double the existing supply. Visit for more info: https://hpvhub.com/a-single-dose-hpv-vaccine-may-be-effective/
In an OBGYN News article published on May 29, 2019, follow-up results from major phase 3 randomized controlled trials of bivalent HPV vaccine in Costa Rica and quadrivalent vaccine in India were shared. These trials deliver promising evidence that a single HPV dose could provide protection against infection for 11 years or more. Since children who receive the vaccine at the recommended age currently receive two doses, this could potentially double the existing supply. Visit for more info: https://hpvhub.com/a-single-dose-hpv-vaccine-may-be-effective/
No comments:
Post a Comment